Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience.
Rituximab
multiple sclerosis
primary progressive
real life
relapsing–remitting
secondary progressive
Journal
Multiple sclerosis (Houndmills, Basingstoke, England)
ISSN: 1477-0970
Titre abrégé: Mult Scler
Pays: England
ID NLM: 9509185
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
pubmed:
2
10
2019
medline:
25
9
2021
entrez:
2
10
2019
Statut:
ppublish
Résumé
Rituximab, an anti-CD20 monoclonal antibody leading to B lymphocyte depletion, is increasingly used as an off-label treatment option for multiple sclerosis (MS). To investigate the effectiveness and safety of rituximab in relapsing-remitting (RR) and progressive MS. This is a multicenter, retrospective study on consecutive MS patients treated off-label with rituximab in 22 Italian and 1 Swiss MS centers. Relapse rate, time to first relapse, Expanded Disability Status Scale (EDSS) progression, incidence of adverse events, and radiological outcomes from 2009 to 2019 were analyzed. A total of 355/451 enrolled subjects had at least one follow-up visit and were included in the outcome analysis. Annualized relapse rate significantly decreases after rituximab initiation versus the pre-rituximab start year in RRMS (from 0.86 to 0.09, Consistently with other observational studies, our data show effectiveness of rituximab in reducing disease activity in patients with MS.
Sections du résumé
BACKGROUND
Rituximab, an anti-CD20 monoclonal antibody leading to B lymphocyte depletion, is increasingly used as an off-label treatment option for multiple sclerosis (MS).
OBJECTIVE
To investigate the effectiveness and safety of rituximab in relapsing-remitting (RR) and progressive MS.
METHODS
This is a multicenter, retrospective study on consecutive MS patients treated off-label with rituximab in 22 Italian and 1 Swiss MS centers. Relapse rate, time to first relapse, Expanded Disability Status Scale (EDSS) progression, incidence of adverse events, and radiological outcomes from 2009 to 2019 were analyzed.
RESULTS
A total of 355/451 enrolled subjects had at least one follow-up visit and were included in the outcome analysis. Annualized relapse rate significantly decreases after rituximab initiation versus the pre-rituximab start year in RRMS (from 0.86 to 0.09,
CONCLUSION
Consistently with other observational studies, our data show effectiveness of rituximab in reducing disease activity in patients with MS.
Identifiants
pubmed: 31573386
doi: 10.1177/1352458519872889
doi:
Substances chimiques
Immunologic Factors
0
Rituximab
4F4X42SYQ6
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM